Pulmatrix Stock Forecast, Price & News

-0.02 (-2.38 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume249,170 shs
Average Volume1.54 million shs
Market Capitalization$46.11 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

Pulmatrix logo

About Pulmatrix

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

913th out of 1,309 stocks

Pharmaceutical Preparations Industry

454th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

Is Pulmatrix a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pulmatrix stock.
View analyst ratings for Pulmatrix
or view top-rated stocks.

What stocks does MarketBeat like better than Pulmatrix?

Wall Street analysts have given Pulmatrix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pulmatrix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pulmatrix?

Pulmatrix saw a drop in short interest in July. As of July 15th, there was short interest totaling 632,500 shares, a drop of 14.2% from the June 30th total of 737,600 shares. Based on an average daily volume of 604,500 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.1% of the shares of the stock are sold short.
View Pulmatrix's Short Interest

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Pulmatrix

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings data on Tuesday, May, 11th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company earned $1.39 million during the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 63.93% and a negative net margin of 166.28%.
View Pulmatrix's earnings history

How has Pulmatrix's stock been impacted by Coronavirus (COVID-19)?

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PULM stock has decreased by 40.6% and is now trading at $0.8198.
View which stocks have been most impacted by COVID-19

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Shares of Pulmatrix reverse split on the morning of Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PULM?

1 brokers have issued 1-year price objectives for Pulmatrix's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Pulmatrix's stock price to reach $5.00 in the next year. This suggests a possible upside of 509.9% from the stock's current price.
View analysts' price targets for Pulmatrix
or view top-rated stocks among Wall Street analysts.

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the following people:
  • Mr. Teofilo David Raad, Pres, CEO & Director (Age 50, Pay $702.97k)
  • Ms. Michelle S. Siegert, VP of Fin. and Principal Financial & Accounting Officer (Age 60, Pay $390.34k)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 72)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 60)
  • Dr. Alexander M. Klibanov Ph.D., Founder (Age 71)
  • Mr. David J. Maki J.D., Advisor (Age 63)

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $0.82.

How much money does Pulmatrix make?

Pulmatrix has a market capitalization of $46.11 million and generates $12.63 million in revenue each year. The biotechnology company earns $-19,310,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Pulmatrix have?

Pulmatrix employs 20 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is

Where are Pulmatrix's headquarters?

Pulmatrix is headquartered at 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.